Gilead joins hands with Cipla, Jubliant and Hetero for the manufacture and distribution of Remdesivir across 127 countries
US pharmaceutical giant, Gilead Sciences has signed non-exclusive voluntary pacts with five other pharma manufacturers across the globe, inclusive of three Indian companies. The move has been initiated in the wake of the recent Covid-19 scare for further expansion of the supply of drug remdesivir, seen as a potential treatment option for COVID-19.
The pacts grant permission to companies- Cipla, Hetero Labs, Jubliant Lifesciences, Mylan and Ferozsons Laboratories from Pakistan for the manufacture and distribution of antiviral drug, Remdesivir across 127 countries.
These include low income countries as well as high income countries that are in the middle of a healthcare crisis in the wake of the recent pandemic.
Mylan is a generic company based in the USA with a humongous subsidiary manufacturing base located in India.
According to the licensing pacts, a technology transfer of the Gilead manufacturing process can be transferred to these countries to augment their production of remdesivir.The licenses set their own prices for the production of the generic products. The licensed have no royalty whatsoever until the World Health Organization (WHO) announces an end to the Public Health Emergency of International Concern in accordance to the coronavirus spread or till another vaccine is approved in place of remdesivir for the treatment or prevention of COVID-19.